Dose increase augments response rate to interferon-alpha in chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C affects millions globally, with interferon-alpha being a primary treatment.
• Standard interferon-alpha doses achieve response in only about 50% of patients.
• Optimizing interferon-alpha therapy is crucial for improving treatment outcomes.

Purpose of the Study:

• To determine if escalating interferon-alpha dosage enhances treatment response in chronic hepatitis C non-responders.
• To evaluate the safety and tolerability of higher interferon-alpha doses.
• To assess sustained viral response after treatment cessation.

Main Methods:

• A randomized controlled trial involving 138 newly diagnosed chronic hepatitis C patients.
• Initial 3-month treatment with 3 MU interferon-alpha2b every two days.
• Non-responders were randomized to continue standard dose or escalate to 6 MU then 10 MU every two days for six months.
• Response defined by normal ALT and undetectable HCV-RNA; liver biopsies performed pre-treatment and post-follow-up.

Main Results:

• Six patients (20%) in the escalated dose group achieved response, compared to none in the standard dose group (P=0.011).
• Higher doses were not tolerated by 20% of patients, with six discontinuing treatment.
• Four of the six responders relapsed during the six-month follow-up period.

Conclusions:

• Escalating interferon-alpha dosage can improve response rates in non-responders to initial therapy.
• Higher-dose interferon-alpha treatment is associated with reduced tolerability.
• Further research into prolonged or optimized interferon-based regimens may be needed for sustained hepatitis C viral clearance.